What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Zejula (Niraparib)

Sezzle
Brand

Zejula (Niraparib)

Prescription Required

Strength
Qty
100mg

You'll have option to make 4 interest-free payments by credit card once your order is confirmed using Sezzle

We don't have this generic product yet!

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

  • Product Details

    Description

    Your doctor may prescribe Zejula for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer.

    Zejula is a poly (ADP-ribose) polymerase (PARP) inhibitor. These drugs work by interfering with the DNA repair mechanisms in cancer cells, ultimately leading to cell death and slowing the progression of the disease.

    Fact Table

    Formula

    C19H20N4O5

    License

    US FDA, EMA

    Bioavailability

    73%

    Legal status

    Prescription only (?)

    Chemical Name

    2-[4-[(3S)-3-piperidinyl]phenyl]-2H-indazole-7-carboxamide

    Elimination half-life

    36 hours

    Dosage (Strength)

    100 mg capsules

    Pregnancy

    Contraindicated

    Brands

    Zejula

    Protein binding

    83%

    PubChem CID

    24958200

    MedlinePlus

    a617038

    ChEBI

    CHEBI:134722

    ATC code

    L01XX54

    DrugBank

    DB12362

    KEGG

    D10867

    Routes of administration

    Oral

    Directions

    The usual dosage is 200-300 mg by mouth once daily. Zejula may be taken with or without food.

    Ingredients

    The active ingredient in Zejula is niraparib.

    Interactions

    There are no significant drug-drug interactions with Zejula

    Cautions

    Cardiovascular side effects like changes in blood pressure and heart rate can occur. Patients should have their blood pressure and heart rate monitored at least weekly for the first two months, then monthly for the first year, and periodically thereafter. Management may include the use of antihypertensive medications and adjustments to the Zejula dose if necessary.

    Zejula has been associated with cases of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), some of which have been fatal. It is crucial to monitor patients for hematological toxicity and discontinue the medication if MDS/AML is confirmed.

    Bone marrow suppression is a significant risk. It is recommended to test blood counts weekly for the first month, then monthly for eleven months, and then periodically thereafter to monitor for clinically significant changes.

    Zejula can cause harm to a fetus. Females of reproductive potential should be advised of the potential risks to a fetus and the necessity of using effective contraception while on this medication.

    Side Effects

    Common adverse effects of Zejula may include:

    • Acute myeloid leukemia
    • Anemia
    • Anemia, Grade 3 or 4
    • Constipation
    • Decrease in appetite
    • Dyspnea
    • Gastrointestinal perforation
    • Headache
    • Hypertension
    • Hypertensive crisis
    • Insomnia
    • Leukopenia, Grade 3 or 4
    • Myelodysplastic syndrome
    • Nasopharyngitis
    • Nausea
    • Neutropenia
    • Neutropenia, Grade 3 or 4
    • Pancytopenia
    • Perforation of small intestine
    • Pleural effusion
    • Posterior reversible encephalopathy syndrome
    • Rash
    • Thrombocytopenia
    • Thrombocytopenia, Grade 3 or 4
    • Vomiting

    References

    Zejula [package insert]. Research Park Triangle, NC: GlaxoSmithKline; April 2020.



    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 14607

  • Product Reviews

Processing..

Please wait while the page is loading. Do not hit refresh or the browser back button to avoid any loss of information.

If you have any questions or concerns, please contact our Customer Service team via the chat option on our website or calling us toll free at: 1-800-891-0844